Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;152 Suppl 1(Suppl 1):101-5.
doi: 10.1159/000312134. Epub 2010 Jun 4.

FIP1L1/PDGFR alpha-associated systemic mastocytosis

Affiliations
Review

FIP1L1/PDGFR alpha-associated systemic mastocytosis

Yoshiyuki Yamada et al. Int Arch Allergy Immunol. 2010.

Abstract

Since the identification of the FIP1L1/PDGFRA fusion gene as a pathogenic cause of the hypereosinophilic syndrome (HES), the importance of the molecular classification of HES leading to the diagnosis of chronic eosinophilic leukemia (CEL) has been recognized. As a result, a new category, 'myeloid and lymphoid neoplasm with eosinophilia and abnormalities in PDGFRA, PDGFRB or FGFR1', has recently been added to the new WHO criteria for myeloid neoplasms. FIP1L1/PDGFR alpha-positive disorders are characterized by clonal hypereosinophilia, multiple organ dysfunctions due to eosinophil infiltration, systemic mastocytosis (SM) and a dramatic response to treatment with imatinib mesylate. A murine HES/CEL model by the introduction of FIP1L1/PDGFR alpha and IL-5 overexpression also shows SM, representing patients with FIP1L1/PDGFR alpha-positive HES/CEL/SM. The murine model and the in vitro development system of FIP1L1/PDGFR alpha-positive mast cells revealed the interaction between FIP1L1/PDGFR alpha, IL-5 and stem cell factor in the development of HES/CEL/SM. Current findings of FIP1L1/PDGFR alpha-positive HES/CEL are reviewed focusing on aberrant mast cell development leading to SM.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Intracellular signaling of FIP1L1/PDGFRα+ (F/P) cells. FIP1L1/PDGFRα+ (F/P) primary mouse eosinophils express up-regulated IL-5Rα and FIP1L1/PDGFRα activates the JAK2/STAT5 pathway. The CCR3/ERK1/2 signaling pathway may be amplified by FIP1L1/PDGFRα expression [25]. Up-regulated expressions of α4 integrin and Siglec-F were observed in FIP1L1/PDGFRα+murine eosinophils [8]. FIP1L1/PDGFRα synergizes with SCF stimulation via c-kit to activate Akt signaling in mouse mast cells. Eosinophils and mast cells also express c-kit and IL-5Rα, respectively.
Fig. 2
Fig. 2
FIP1L1/PDGFRα in conjunction with SCF and IL-5 promote leukemic hematopoiesis and eosinophil and mast cell (MC) development. FIP1L1/PDGFRα may occur in hematopoietic stem cells or early progenitor cells resulting in the expression of FIP1L1/PDGFRα in most hematopoietic cells. Progenitors including earlier and mature eosinophils and MCs express c-kit. In contrast, IL-5Rα expression has been observed on eosinophil progenitor (EoP), MC progenitor (MCP) and mature eosinophils and MCs. FIP1L1/PDGFRα enhances SCF/c-kit signaling by sharing downstream signaling and up-regulates IL-5Rα expression facilitating its intracellular signaling. There is significant crosstalk between eosinophils and MCs. These findings imply that FIP1L1/ PDGFRα in collaboration with SCF may affect leukemic myeloproliferation, and synergistically with IL-5 expand and activate MC and eosinophil lineages. ST-HSC = Short-term HSC; CMP = common myeloid progenitor; GMP = granulocyte-macrophage progenitor.

Similar articles

Cited by

References

    1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214. - PubMed
    1. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol. 2007;138:77–81. - PubMed
    1. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC. Identification of a novel imatinib-responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827–832. - PubMed
    1. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, Erben P, Muller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer. 2006;45:950–956. - PubMed
    1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22. - PubMed

Publication types

MeSH terms

Substances